A Study of LY3537031 in Healthy Participants
Launched by ELI LILLY AND COMPANY · Nov 24, 2020
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Are male or female not of childbearing potential
- • Have a body mass index (BMI) between 19 and 35 kilograms per square meter (kg/m²) and a body weight ≥ 54 kilograms (kg)
- • Have blood pressure, pulse rate, blood and urine laboratory test results that are acceptable for the study
- • Have veins suitable for blood sampling
- Exclusion Criteria:
- • Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
- • Have a diagnosis or history of cancer or malignant disease within 5 years
- • Have been treated with prescription and over-the-counter medications that promote weight loss within 3 months prior to screening
- • Show clinical evidence of syphilis, HIV, hepatitis C, or hepatitis B, and/or test positive
- • Have undergone any form of bariatric surgery
- • Have previously completed or withdrawn from this study
- • Are currently participating in or completed a clinical trial within the last 3 months
- • Regularly use known drugs of abuse or with positive drug results
- • Smoke \>10 cigarettes per day or the equivalent, or are unable or unwilling to refrain from nicotine during CRU admission
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shinjuku Ku, Tokyo, Japan
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials